


How to Use Actim® PROM and Actim® Partus Test Kits




ACTIM® PARTUS RAPID TEST

- The reliable way to identify and rule out the risk of preterm and imminent delivery
- Can be used from 22 weeks onwards^{1,2}
- Intercourse, semen, urine, vaginal infections, vaginal medications, lubricants or bathing products do not interfere with test results¹⁻³
- Approximately two out of three symptomatic patients get a negative test result
- Negative predictive value (NPV) of the test is 92%–98%⁴⁻⁹
- Unnecessary treatments with potential side effects can be avoided, the mother is given peace of mind and hospital resources are saved

ACTIM® PROM RAPID TEST

- First rapid test that reliably detects premature rupture of membranes (PROM), even before any clinically visible signs
- Can be used at any gestational age³
- Test results are not affected by blood, intercourse, semen, urine, vaginal medications, lubricants, bathing products or infections¹⁰⁻¹⁵
- Detects even the smallest rupture with high sensitivity: 95%–100%^{10,12,14,16,17}
- Approximately 50% of tested patients get a positive test result
- Unnecessary use of medications with their side effects, labor induction and hospital stays can be avoided, and reliable results give expecting mother peace of mind

Sample Collection and Assay Procedure



ORDERING INFORMATION

Product Name	Product No.
ACTIM® PROM 10T (VISUAL READ)	30831ETAL
ACTIM® PROM 20T (VISUAL READ)	30832ETAL
ACTIM® PROM 1NGENI 20T	30832RETAL
ACTIM® PARTUS 10T (VISUAL READ)	31931ETAL
ACTIM® PARTUS 1NGENI 10T	31931RETAL
ACTIM® 1NGENI INSTRUMENT	19100AC



**ACTIM® PARTUS
1NGENI PROVIDES A
QUANTITATIVE RESULT**

FOR MORE INFORMATION, CONTACT YOUR LOCAL ABBOTT REPRESENTATIVE OR VISIT GLOBALPOINTOFCARE.ABBOTT

T: 1800 622 642 (free call AU) | T: 0800 466 951 (free call NZ) | T: +61 7 3363 7100 | rapiddx.ANZ.enquiries@abbott.com

- Kekki, M. et al., 2001. Insulin-like growth factor-binding protein-1 in cervical secretion as a predictor of preterm delivery. *Acta Obstetrica et Gynecologica Scandinavica*, 80(6), pp.546-551.
- Rahkonen, L. et al., 2008. Factors affecting decidual IGFBP-1 levels in the vagina and cervix in the first and mid-second trimester of pregnancy. *BJOG: An International Journal of Obstetrics & Gynaecology*, 116(1), pp.45-54.
- Rutanan, E. et al., 1993. Measurement of insulin-like growth factor binding protein-1 in cervical/vaginal secretions: comparison with the ROM-check membrane immunoassay in the diagnosis of ruptured fetal membranes. *Clinica Chimica Acta*, 214(1), pp.73-75.
- Azlin, M. et al., 2010. Role of pHIGFBP-1 and ultrasound cervical length in predicting pre-term labour. *Journal of Obstetrics and Gynaecology*, 30(5), pp.456-459.
- Brik, M. et al., 2010. Phosphorylated insulin-like growth factor binding protein-1 and cervical measurement in women with threatening preterm birth. *Acta Obstetrica et Gynecologica Scandinavica*, 89(2), pp.268-274.
- Eroglu, D. et al., 2007. Prediction of Preterm Delivery among Women with Threatened Preterm Labor. *Gynecologic and Obstetric Investigation*, 64(2), pp.109-116.
- Lembet, A. et al., 2002. New rapid bed-side test to predict preterm delivery: phosphorylated insulin-like growth factor binding protein-1 in cervical secretions. *Acta Obstetrica et Gynecologica Scandinavica*, 81(8), pp.706-712.
- Tanir, H. et al., 2009. Cervical phosphorylated insulin-like growth factor binding protein-1 for the prediction of preterm delivery in symptomatic cases with intact membranes. *Journal of Obstetrics and Gynaecology Research*, 35(1), pp.66-72.
- Ting, H. et al., 2007. Comparison of bedside test kits for prediction of preterm delivery: Phosphorylated insulin-like growth factor binding protein-1 (pIGFBP-1) test and fetal fibronectin test. *Annals of the Academy of Medicine, Singapore*, 36(6), pp.399-402.
- Rutanan, E. et al., 1996. Evaluation of a rapid strip test for insulin-like growth factor binding protein-1 in the diagnosis of ruptured fetal membranes. *Clinica Chimica Acta*, 253(1-2), pp.91-101.
- Gaucherand, P. et al., 1997. Comparative study of three vaginal markers of the premature rupture of membranes: Insulin like growth factor binding protein 1 Diamine-oxidase pH. *Acta Obstetrica et Gynecologica Scandinavica*, 76(6), pp.536-540.
- Kubota, T. and Takeuchi, H., 1998. Evaluation of Insulin-Like Growth Factor Binding Protein-1 as a Diagnostic Tool for Rupture of the Membranes. *Journal of Obstetrics and Gynaecology Research*, 24(6), pp.411-417.
- Guibourdenche, J. et al., 1999. Rapid Detection of Insulin-Like Growth Factor-Binding Protein-1 and Foetal Fibronectin in Cervico-Vaginal Secretions to Diagnose Premature Membrane Rupture. *Annals of Clinical Biochemistry: An international journal of biochemistry and laboratory medicine*, 36(3), pp.388-390.
- Erdemoglu, E. and Mungan, T., 2004. Significance of detecting insulin-like growth factor binding protein-1 in cervicovaginal secretions: comparison with nitrazine test and amniotic fluid volume assessment. *Acta Obstetrica et Gynecologica Scandinavica*, 83(7), pp.622-626.
- Novikova, SV. et al., 2007. Verification of premature rupture of membranes using the express test Actim PROM. *Voprosy ginekologii, akusherstva i perinatologii*, 6 (5), pp.102-105.
- Ragosch, V. et al., 1996. Insulin like growth factor binding protein 1 (IGFBP-1) und fetales Fibronectin in der Diagnostik eines vorzeitigen Blasensprunges. *Geburtshilfe und Frauenheilkunde*, 56(06), pp.291-296.
- Jain, K. and Morris, P., 1998. A clinical study to evaluate the usefulness of the MAST test in diagnosing pre-labour rupture of membranes. *Journal of Obstetrics and Gynaecology*, 18(1), pp.33-36.